product7/Ruxolitinib-phosphate.html

Ruxolitinib phosphate (INCB018424)(INCB018424 phosphate) is the first potent, selective, JAK1 2 inhibitor to enter the clinic with IC50 of 3.3 nM 2.8 nM, >130-fold selectivity for JAK1 2 versus JAK3.

D-Sedoheptulose-7-phosphate is an intermediate in the pentose phosphate pathway. [1] [2] In this pathway, transaldolase catalyzes the transfer of a three carbon dihydroxyacetone moiety from D-sedoheptulose-7-phosphate to glyceraldehyde-3-phosphate to generate D-fructose-6-phosphate . D-Sedoheptulose-7-phosphate is also an intermediate in carbon fixation in photosynthetic organisms, as well as in the biosynthesis of lipopolysaccharide, amino acids, secondary metabolites, and antibiotics. [3]

D-Sedoheptulose 7-phosphate is a common precursor of heptaic acid (group III) and the heptasaccharide of hygromycin B (group IV). This compound can be converted to NDP-heptose via similar biosynthetic pathways present in these substances.